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1. Introduction 
Cancer development is generally depicted as successive waves of Darwinian selection of 
cells harbouring genetic and epigenetic abnormalities, providing them with proliferative, 
survival and adaptive advantages. As genetic alterations preferentially operate on naked 
DNA, original targeted cells are presumably either proliferating or engaged in a 
reprogramming process, both cellular mechanisms being associated with chromatin 
decondensation. Taking this point in consideration, appropriate candidates include a large 
set of embryonic cells (or embryonic stem-cells) as well as adult stem/progenitor cells when 
engaged in a repopulation process, a mechanism either permanent as in regenerative tissues 
such as the intestine, the colon or the skin, or sporadically induced in response to insults, 
such as wound healings. Studies of hematopoietic cancers point out that the malignancy 
might originate from the alteration of a single cell displaying both self-renewal and 
differentiation potentials. By similarity with normal stem-cells, that are able to reconstitute a 
complete tissue, this observation led to the development of the “cancer stem-cell” (CSC) 
concept. Indeed, in chronic myeloid leukaemia (CML), several type of blood cells including 
their most primitive precursors display a similar chromosomal recombination (named the 
Philadelphia chromosome) leading to the production of the aberrant BCR-ABLp120 fusion 
protein. This genetic alteration was therefore likely to drive transformation of precursor cells 
or stem-cells, deregulating the production of mature cells without affecting their ability to 
execute their normal differentiation (Bonnet and Dick, 1997). Accordingly, the restricted 
expression of the aberrant BCR-ABLp120 fusion protein in Sca1+ stem-cells was shown, in 
transgenic mice, to mimic human CML, characterized by a progression from chronic 
towards an acute phase (Perez-Caro et al., 2009). While the inhibition of the activity of the 
kinase by the ST1571 chemical compound, according to the resistance of the human 
leukaemia stem cells to the chemical (Graham et al., 2002; Hu et al., 2006; Primo et al., 2006; 
Jiang et al., 2007), did not modify the survival of the transgenic mice, CSC ablation 
eradicated tumours, demonstrating undoubtedly their role in AML development and the 
therapeutic interest of eradicating them (Perez-Caro et al., 2009). Since then, a large number 
of laboratories attempt to extend the CSC theory to solid tumours. The observation that 
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metastases and their original primary tumour share a similar heterogeneity indeed argue in 
favour of the presence of a subset of CSCs displaying both self-renewing and differentiation 
capabilities. In such a scenario, CSCs are expected to represent a minor population of the 
tumour, giving rise to differentiated cells that, per definition, would have lost their self-
renewal capabilities and thereby their tumour driving potential. In the last decade, based on 
phenotypic and/or functional similarities with their normal counterparts, CSCs have been 
successfully isolated form numerous cancer types, including breast tumours, gliomas and 
melanomas and described as displaying self-renewal and differentiation properties. 
Validating the concept that a limited number of cells resulting from the transformation of 
normal stem-cells continuously fuel the tumour has constituted a real breakthrough in the 
cancer field and has had major repercussions in the design of novel therapeutic approaches. 
Nonetheless, as discussed below, several of the experimental assays commonly used to 
evaluate stem-like properties are individually questionable. These doubts raise some 
concerns on the real biological properties of the isolated CSC subpopulations and impact on 
the current debate concerning their potential origin. Noticeably, even the term of “cancer 
stem-cells” is probably not appropriated referring to their normal counterparts. Although 
some adult normal stem-cells were found to be highly proliferative (Barker et al., 2009), they 
generally are depicted as poorly proliferating cells, able to concomitantly maintain their 
pool and generate their progeny through asymmetric divisions. As far as we know, if the 
proportion of CSC is maintained during tumour growth, this is far away of demonstrating 
that they actually share this same property. The potential filiation between normal stem-
cells and CSCs thus remains a matter of discussion, leading to the emergence of the 
alternative “tumour-initiating cells” terminology.  
The questionable characterisation of CSC 
In this first section, we will attempt to demonstrate the limit of the techniques currently 
used for isolating CSCs and the conflicting results they provide. These techniques consist in 
identifying CSCs by exploiting expected similarities with their normal counterparts, 
including some phenotypic features, their ability to efflux drugs and to grow as 
colonospheres, when cultured in low adherent conditions. Sorting CSC from tumours or 
tumour cell lines, taking advantage of specific stem-cell markers, is a commonly used 
approach but in fine turned out to be more difficult as previously thought. A major reason is 
that this notion of “specificity” is often biased by the quality of the available antibodies used 
and by our current limited knowledge on normal stem cell features. A significant example is 
provided by the contradictory results generated by using the transmembrane protein CD133 
as a stem-cell marker. In numerous studies, monoclonal antibodies to CD133 were defined 
as appropriate tools to isolate CSC from various tumour types (Barker et al., 2009; Yin et al., 
1997; Uchida et al., 2000; Lee et al., 2005; Sagrinati et al., 2006; Richardson et al., 2004; Kordes 
et al., 2007; Oshima et al., 2007; Sugiyama et al., 2007; Ito et al., 2007). Nonetheless, by 
generating transgenic mice expressing the LacZ reporter gene under the control of the 
CD133 promoting sequences, the transmembrane protein was found expressed by mature 
luminal ductal epithelial cells in adult organs, suggesting that it is not a specific marker of 
stem-cells (Shmelkov et al., 2008).  The interest in using CD133 was further challenged, as 
these authors next demonstrated, taking advantage of IL10 knock-out mice, that cancer cells 
in primary colon carcinomas uniformly express CD133. Evenmore, CD133+ and CD133- cells 
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isolated from secondary tumours display similar tumorigenic potential, as assessed by serial 
transplantations into immuno-compromised mice, and were both capable of forming 
colonospheres in vitro at a similar rate (Shmelkov et al., 2008).   
The ability of stem cells to efflux drugs, due to a high expression level of transporters, was 
also exploited for isolating CSCs. This approach led to the detection by flow cytometry of a 
population of cells named side population (SP), able to efflux the DNA binding Hoechst 
3342 dye. Unfortunately SP and CSC populations do not always match. In mice bone 
marrows, SP subpopulation was originally found to be enriched in hematopoietic stem cells 
(Goodell et al., 1996). Consistently, progenitor cells were restricted to the SP fraction of 
mammospheres (Dontu et al., 2003) and SP purified from several cancer cell lines show 
enhanced tumorigenicity in vivo relative to their non-SP cohorts (Ho et al., 2007; Patrawala et 
al., 2005). Nonetheless, in some tumor types, SP populations are not enriched in SSC 
(Mitsutake et al., 2007; Stingl et al., 2006; Burger et al., 2004) and purified mouse mammary 
SP cells do not efficiently repopulate the mammary gland in a reconstitution assay (Alvi et 
al., 2003). This discrepancy is likely to reflect the existence of various cell populations that 
actually share with stem-cells a set of common properties.  
Enrichment in stem-cells in low adherent culture conditions is an additional commonly used 
approach to isolate CSC. This technology was originally performed to evaluate the self-
renewal capacity of neural cells (Reynolds and Weiss, 1996), next adopted for human breast 
epithelial cells to form mammospheres (Dontu et al., 2003) and finally extended to various 
cancer types. Individual cells able to grow in low adherent conditions for up to five 
consecutive passages indeed display a gene expression profile consistent with progenitor 
properties, validating the experimental approach. These conditions might however simply 
select for cells displaying resistance to anoïkis. One could easily envisage that the stress 
conditions provided by the low adherence actually enforce cells to adapt through a genomic 
reprogramming, potentially a partial dedifferentiation, leading to the expression of some 
stem cell-associated genes. Evenmore, the function of normal stem cells is highly regulated 
by their niche through direct and paracrine interactions with supporting cells and the 
extracellular matrix. One could then wonder why in sphere cultures, in absence of this 
niche, cells might display stem-cell properties.  
A more recent assay has consisted in purifying CSC based on the detoxifying aldehyde 
dehydrogenase 1 (ALDH1) enzymatic activity,  previously detected in a set of normal stem-
cells (Armstrong et al., 2004; Matsui et al., 2004; Hess et al., 2004). Nonetheless, attempts to 
isolate breast CSCs according to their antigenic phenotype or to their ALDH1 activity led 
again to the isolation of different cell subpopulations that at the most partially overlap, 
suggesting that actually any of these markers are strictly allotted to stem-cells (Al-Hajj et al., 
2003; Fillmore and Kuperwasser, 2008; Ginestier et al., 2007). 
The stem cell potentiality of the presumed isolated CSC subpopulations is next evaluated 
through various functional assays. As theoretically, a single CSC should be able to 
reconstitute a complete tumour, a commonly used assay consists in evaluating their 
tumorigenic potential when xenografted at limit dilutions in immunosuppressive mice. This 
assay turns out being also questionable. Considering that cells have to evade from the 
immune system (even in immuno-compromised hosts), their antigenic phenotype and their 
immunosuppressive properties might impinge on their tumorigenic potential.  Moreover, 
their ability to interfere with the host environment is undoubtedly a limiting factor.  Taking 
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this information in consideration, optimisation of the experimental conditions, including 
selection of more highly immuno-compromised or humanised mice, dramatically increased 
the detectable frequency of tumorigenic cells (Quintana et al., 2008). One fourth of 
melanoma cells were thus found to display a tumorigenic potential, independently of their 
CD133 antigenic phenotype (Quintana et al., 2008). Consistently, a large proportion of cells 
isolated from primary Eμ-Myc pre-B/B lymphoma, Eμ-N-Ras thymic lymphomas and PU.1-
/- acute myeloid leukaemia sustain tumour growth when transplanted in NOD/SCID 
immuno-deficient mice, challenging the concept that tumours arise from rare CSCs, at least 
for malignancies with substantial homogeneity (Kelly et al., 2007). Recently, the Herlyn 
laboratory actually demonstrated that CSCs did not contribute to tumour initiation but were 
rather found as essential for long term maintenance, as judged by serial transplantations in 
nude mice (Roesch et al., 2010).  Finally, transplantations in mice are generally performed 
with individualised cells, although maintaining them in a niche has recently been shown as 
determinant for their tumorigenic potential (Liu et al., 2009).  Conclusions based on 
xenograft experiments should therefore be considered with caution.  
If CSCs are able to reconstitute the heterogeneous populations of a primary tumour, they are 
additionally suggested to display a differential potential (Dirks, 2008). As previously 
mentioned, CSCs are often sorted out of primary tumours/cell lines based on the expression 
of specific antigens. By definition, the non cancer stem-cell subpopulation that presumably 
represents the large pool of differentiated cells constituting the bulk of the tumour is 
represented by the cellular fraction lacking this specific marker. The differentiation potential 
of the presumed isolated CSCs often relies on their ability to evolve into their differentiated 
counterparts. While this shift is likely to reflect some reprogramming, these data are far 
away from demonstrating pluri-potentiality, with a potential to commit into various 
differentiation programs. At the most, transplantation of these cells in mice gives rise to 
tumours that display a similar heterogeneity as the primary tumours they originate from. 
Whether this heterogeneity reflects an adaptive partial reprogramming rather than a 
dedifferentiation-differentiation process is plausible.  
In conclusion, various recent observations reveal the intrinsic limits of each of these 
experimental approaches.  While combining them is probably helpful in interpreting the 
results, it is obviously not sufficient, implying the development of additional tools. The 
establishment of novel transgenic mouse models is undoubtedly a promising alternative in 
further exploring tumour initiation. As a first example, the activation of the Wnt pathway in 
LG5+/CD133+ or Bmi1+ intestine stem cells was recently found to promote adenomas while 
it fails to do so when induced in short-lived transit amplifying cells (Barker et al., 2009; Zhu 
et al., 2009). These studies provide first evidences that a window of time exists for mutations 
in intestinal epithelial cells to initiate tumour formation. More sophisticated engineered 
transgenic mouse models, recapitulating the sequential accumulation of genetic alterations 
will probably be of further help in understanding the tumour progression process in the 
next future.   
Origins of CSCs 
While some studies suggest that CSC may arise from the transformation of their normal 
counterparts, recent observations rather suggest that they originate from fully differentiated 
cells through an adaptive transdifferentiation program (Figure 1). This hypothesis originally  
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Fig. 1. The “cancer stem-cell theory” (panel A) is based on the assumption that during tissue 
regeneration, the amplification of progenitor cells opens a window of time suitable for 
accumulating genetic alterations, leading to the emergence of cancer cell-stems (CSCs). CSCs 
would thus initiate and sustain tumour growth.  
Alternatively, under stress conditions, fully differentiated cells reacquire stem-like 
properties, including self-renewal properties (panel B). This gain of function is influenced by 
cellular intrinsic properties as well as micro-environmental conditions. These cells could 
potentially be prone to transformation and give rise to CSCs.  
Both models are not exclusive. CSCs and cell dedifferentiation would thus constitute the 
initial and secondary tumour drivers, respectively. 
emerges from in vitro cell transformation assays. Transformation of human mammary 
epithelial cells (HMECs) consisted in sequentially infecting cells with the catalytic sub-unit 
of the telomerase (immortalisation step), the SV40 T/t antigens (these viral proteins have 
pleiotropic effects including the neutralisation of both Rb- and p53-dependent-
oncosuppressive pathways) and an activated version of the mitogenic protein Ras (H-
RasG12V) (Elenbaas et al., 2001). Cell transformation was found to be invariably associated 
with cellular morphological changes associated with an epithelial-mesenchymal transition 
(EMT) (Morel et al., 2008; Mani et al., 2008). EMT is a trans-differentiation process that 
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consists in turning polarized and adjacent epithelial cells into individual and motile 
mesenchymal ones. Originally identified as a biological process essential for the 
morphogenetic movements during the embryonic development, its aberrant reactivation in 
cancers is currently considered as one of the main driving cancer cell dissemination (Thiery 
et al., 2009). Studying the contribution of EMT in cell transformation led to the 
demonstration that it actually constitutes a dedifferentiation process, providing cells with 
some stem-like properties (Morel et al., 2008; Mani et al., 2008; Vesuna et al., 2009). Cells that 
have undergone an EMT were thus found to form mammospheres in low adherent 
conditions and to be highly tumorigenic when orthotopically xenografted at limit dilution in 
nude mice. They additionally display a CD44high CD24low antigenic phenotype that was 
previously allotted to mammary CSCs (Al-Hajj et al., 2003). EMT being by definition a 
reversible process, these cells continuously generate CD44low CD24high epithelial cells that 
interestingly lack a tumorigenic potential (Morel et al., 2008; Mani et al., 2008; Vesuna et al., 
2009). In regards to the EMT-associated properties, the transdifferentiation process was thus 
considered as a biological process able to convert differentiated epithelial cells into CSCs. 
EMT being strongly impacted by micro-environmental conditions, the balance between 
differentiated cells and CSCs was then proposed to be a highly dynamic process with 
important repercussions on therapeutic approaches, eradication of the entire primary 
tumour, including differentiated cells, being henceforth a requisite to prevent recurrence 
(Gupta et al., 2009).  
Despite the obvious interest of these works, we still can emit some reserve about their 
meaning. Obviously, EMT is a reversible transdifferentiation process associated with a 
profound genetic reprogramming and major consequent phenotypic changes. Considering 
that mesenchymal cells display a pluripotency based on their ability to turn into epithelial 
ones, is probably a miss-interpretation, rather reflecting the equilibrium between the two 
cell fates of this transdifferentiation process. Recently, in appropriate culture conditions, 
HMEC-transformed mesenchymal derivatives were found to initiate chondrocytic, 
adipocytic or osteoblastic differentiation programs, highlighting their pluripotency (Battula 
et al., 2010). Nonetheless, as previously mentioned, these cells harbour a set of genetic 
alterations, including the expression of viral proteins which are known to impact on 
multiple cellular functions. Whether similar results would be obtained in more 
“physiological” conditions, by combining EMT-permissive conditions with a restricted 
number of genetic events, is warranted to further evaluate the relevance of these 
observations. The CSC features of these HMEC derivatives were next supported by their 
tumorigenic potentials at limiting conditions. If CSCs are rather important for tumour 
maintenance than for tumour initiation (Roesch et al., 2010), this result would more 
highlight a direct role of EMT in facilitating cell transformation and tumour initiation. 
Finally, these cells were described as displaying a similar antigenic phenotype as the one 
originally attributed to mammary CSCs (Al-Hajj et al., 2003) Nonetheless, likewise the 
CD133+ population, CD44highCD24low cells might actually include much more than the CSCs, 
which antigenic phenotype has been restricted to CD44highCD24lowESA+ or 
CD44highCD24lowALDH1+ cells (Fillmore and Kuperwasser, 2008; Ginestier et al., 2007). 
Rather than providing cells with real stem-like properties, EMT might actually provide cells 
with some plasticity, facilitating potentially the transformation process and helping them to 
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adapt to microenvironmental changes. In other terms, this plasticity and adaptation to 
microenvironmental changes implies that CD44highCD24low mesenchymal cells constitute a 
pool of tumour-driving cells whereas the CD44lowCD24high epithelial counterparts behave as 
a latent reserve of cancer cells reactivated in hostile conditions. In line with such a model, 
when exposed to EGFR tyrosine kinase inhibitor (TKI), a minor subpopulation of non small 
cell lung cancer derived cells that express some stem-cell-associated antigens (such as 
CD133) adopt a quiescent phenotype and resistance. Emergence of these resistant clones is 
abrogated in presence of trichostatin, an inhibitor of histone deacetylases, suggesting that it 
reflects a transient reprogramming, involving epigenetic changes, rather than an enrichment 
of a pre-existing cell subpopulation. When maintained in presence of TKI, a proportion of 
these cells restarts proliferating, giving rise to resistant cell lines that revert to a sensitive 
stage when released from the drug (Sharma et al., 2010). Cell reprogramming thus provides 
a route for cells to adapt to hostile conditions, a mechanism that the authors interestingly 
compare to the antibiotic-tolerant bacterial subpopulations termed “persisters” (Sharma et 
al., 2010). By similarity, EMT might be an escape from hypoxic conditions and mechanical 
constrains and the stem-like features associated with, just be a mirror of this adaptative 
process. Whether these cells are particularly prone to transformation, in light of their 
proliferation capabilities, remains to be determined. Some genetic events might similarly 
favour cell dedifferentiation into CSCs. Indeed, murine fibroblasts lacking the RB proteins 
were found to generate colonospheres at confluency and to reconstitute monolayers when 
plated at lower density. Interestingly, these colonospheres were found to be tumorigenic 
when xenografted in mice at limit dilutions, to include a SP, to express stem-cell markers 
and to additionally display differentiation properties (Liu et al., 2009). In conclusion, this 
plasticity might provide cells with survival advantages, when placed in hostile conditions. 
Overall, these recent observations demonstrate that the stem-like properties harboured by 
numerous cancer cells do not rely on any particular relationship to normal stem-cells but 
rather reflect the Darwinian selection that operates within a tumour.  
Evolution of the concepts and therapeutic consequences 
According to the CSC theory, eradicating the rare CSCs would be sufficient to clear 
tumours. A selection step implying a gain in plasticity and adaptation potential rather 
suggests that the eradication of all cancer cells, including the differentiated ones, is actually 
a requisite to eliminate all risks of recurrence. Beyond the cognitive interest, the origin of 
CSCs might impact on the design of future therapies. If CSCs display a low proliferation 
potential, they are supposed to be resistant to standard radio- or chemotherapies. Evenmore, 
these treatments could have the noxious effect to enforce differentiated cancer cells to evolve 
into tumour-driving ones. Numerous studies are currently engaged to determine the 
relative importance of various signalling pathways in these cells. The design of additional 
drugs that might additionally annihilate the dedifferentiation potential of the differentiated 
cancer cells should also be considered. Obviously, drugs preventing transient epigenetic 
changes, such as the histone deacetylase (HDAC) inhibitor trichostatin (TSA) might be 
appropriate (Sharma et al., 2010). Recently, numerous histone deacetylase inhibitors have 
been identified and some were recently found as efficient in clinical trials for cancer treating 
(for recent reviews see Lane and Chabner, 2009; Sebova and Fridrichova, 2010). 
Alternatively, one could also envisage that the plasticity is maintained to some extent and 
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engaging cells further in a differentiation program might avoid them to rescue from insults, 
potentially explaining the synergistic effect of some differentiation agents and radiation in 
eradicating xenografted tumours (Kawamata et al., 2006). 
2. Conclusions 
The relevance of the cancer-stem cell theory and the origin of CSCs remains currently a 
matter of discussion. The interpretation of the data obtained in this field is complicated by 
the fact that selection pressures enforce cancer cells to constantly evolve and gain in 
plasticity. Adaptation to hostile environment is likely driven by transient dedifferentiation 
processes, likely associated with the acquisition of some stem-like properties. The co-
existence of various cancer cell populations within a primary tumour makes the 
interpretation of the results somehow difficult. Further investigations with help from novel 
techniques, including sophisticated transgenic mouse models, will probably clarify the 
current debate. Undoubtedly, these fields of research will shed light on impenetrable aspects 
of the tumorigenesis and open up new horizons for eradicating cancers. 
3. References 
Al-Hajj,M., Wicha,M.S., ito-Hernandez,A., Morrison,S.J., and Clarke,M.F. (2003). Prospective 
identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A 100, 
3983-3988. 
Alvi,A.J., Clayton,H., Joshi,C., Enver,T., Ashworth,A., Vivanco,M.M., Dale,T.C., and 
Smalley,M.J. (2003). Functional and molecular characterisation of mammary side 
population cells. Breast Cancer Res. 5, R1-R8. 
Armstrong,L., Stojkovic,M., Dimmick,I., Ahmad,S., Stojkovic,P., Hole,N., and Lako, 
M. (2004). Phenotypic characterization of murine primitive hematopoietic 
progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 
22, 1142-1151. 
Barker,N., Ridgway,R.A., van Es,J.H., van de,W.M., Begthel,H., van den,B.M., Danenberg,E., 
Clarke,A.R., Sansom,O.J., and Clevers,H. (2009). Crypt stem cells as the cells-of-
origin of intestinal cancer. Nature 457, 608-611. 
Battula,V.L., Evans,K.W., Hollier,B.G., Shi,Y., Marini,F.C., Ayyanan,A., Wang,R.Y., 
Brisken,C., Guerra,R., Andreeff,M., and Mani,S.A. (2010). Epithelial-Mesenchymal 
Transition-Derived Cells Exhibit Multi-Lineage Differentiation Potential Similar to 
Mesenchymal Stem Cells. Stem Cells. 
Bonnet,D. and Dick,J.E. (1997). Human acute myeloid leukemia is organized as a hierarchy 
that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737. 
Burger,H., van,T.H., Boersma,A.W., Brok,M., Wiemer,E.A., Stoter,G., and Nooter,K. (2004). 
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein 
(BCRP)/ABCG2 drug pump. Blood 104, 2940-2942. 
Dirks,P.B. (2008). Brain tumor stem cells: bringing order to the chaos of brain cancer. J. Clin. 
Oncol. 26, 2916-2924. 
www.intechopen.com
From where do Cancer-Initiating Cells Originate?   
 
43 
Dontu,G., Abdallah,W.M., Foley,J.M., Jackson,K.W., Clarke,M.F., Kawamura,M.J., and 
Wicha,M.S. (2003). In vitro propagation and transcriptional profiling of human 
mammary stem/progenitor cells. Genes Dev. 17, 1253-1270. 
Elenbaas,B., Spirio,L., Koerner,F., Fleming,M.D., Zimonjic,D.B., Donaher,J.L., Popescu,N.C., 
Hahn,W.C., and Weinberg,R.A. (2001). Human breast cancer cells generated by 
oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15, 50-
65. 
Fillmore,C.M. and Kuperwasser,C. (2008). Human breast cancer cell lines contain stem-like 
cells that self-renew, give rise to phenotypically diverse progeny and survive 
chemotherapy. Breast Cancer Res. 10, R25. 
Ginestier,C., Hur,M.H., Charafe-Jauffret,E., Monville,F., Dutcher,J., Brown,M., Jacquemier,J., 
Viens,P., Kleer,C.G., Liu,S., Schott,A., Hayes,D., Birnbaum,D., Wicha,M.S., and 
Dontu,G. (2007). ALDH1 is a marker of normal and malignant human mammary 
stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567. 
Goodell,M.A., Brose,K., Paradis,G., Conner,A.S., and Mulligan,R.C. (1996). Isolation and 
functional properties of murine hematopoietic stem cells that are replicating in 
vivo. J. Exp. Med. 183, 1797-1806. 
Graham,S.M., Jorgensen,H.G., Allan,E., Pearson,C., Alcorn,M.J., Richmond,L., and 
Holyoake,T.L. (2002). Primitive, quiescent, Philadelphia-positive stem cells from 
patients with chronic myeloid leukemia are insensitive to STI571 in vitro 
. Blood 99, 319-325. 
Gupta,P.B., Chaffer,C.L., and Weinberg,R.A. (2009). Cancer stem cells: mirage or reality? 
Nat. Med. 15, 1010-1012. 
Hess,D.A., Meyerrose,T.E., Wirthlin,L., Craft,T.P., Herrbrich,P.E., Creer,M.H., and Nolta,J.A. 
(2004). Functional characterization of highly purified human hematopoietic 
repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 
104, 1648-1655. 
Ho,M.M., Ng,A.V., Lam,S., and Hung,J.Y. (2007). Side population in human lung cancer  
cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827-
4833. 
Hu,Y., Swerdlow,S., Duffy,T.M., Weinmann,R., Lee,F.Y., and Li,S. (2006). Targeting  
multiple kinase pathways in leukemic progenitors and stem cells is essential for 
improved treatment of Ph+ leukemia in mice. Proc. Natl. Acad. Sci. U. S. A 103, 
16870-16875. 
Ito,Y., Hamazaki,T.S., Ohnuma,K., Tamaki,K., Asashima,M., and Okochi,H. (2007). Isolation 
of murine hair-inducing cells using the cell surface marker prominin-1/CD133. J. 
Invest Dermatol. 127, 1052-1060. 
Jiang,X., Zhao,Y., Smith,C., Gasparetto,M., Turhan,A., Eaves,A., and Eaves,C. (2007). 
Chronic myeloid leukemia stem cells possess multiple unique features of resistance 
to BCR-ABL targeted therapies. Leukemia 21, 926-935. 
Kawamata,H., Tachibana,M., Fujimori,T., and Imai,Y. (2006). Differentiation-inducing 
therapy for solid tumors. Curr. Pharm. Des 12, 379-385. 
Kelly,P.N., Dakic,A., Adams,J.M., Nutt,S.L., and Strasser,A. (2007). Tumor growth need not 
be driven by rare cancer stem cells. Science 317, 337. 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
44 
Kordes,C., Sawitza,I., Muller-Marbach,A., le-Agha,N., Keitel,V., Klonowski-Stumpe,H., and 
Haussinger,D. (2007). CD133+ hepatic stellate cells are progenitor cells. Biochem. 
Biophys. Res. Commun. 352, 410-417. 
Lane,A.A. and Chabner,B.A. (2009). Histone deacetylase inhibitors in cancer therapy. J. Clin. 
Oncol. 27, 5459-5468. 
Lee,A., Kessler,J.D., Read,T.A., Kaiser,C., Corbeil,D., Huttner,W.B., Johnson,J.E., and 
Wechsler-Reya,R.J. (2005). Isolation of neural stem cells from the postnatal 
cerebellum. Nat. Neurosci. 8, 723-729. 
Liu,Y., Clem,B., Zuba-Surma,E.K., El-Naggar,S., Telang,S., Jenson,A.B., Wang,Y., Shao,H., 
Ratajczak,M.Z., Chesney,J., and Dean,D.C. (2009). Mouse fibroblasts lacking RB1 
function form spheres and undergo reprogramming to a cancer stem cell 
phenotype. Cell Stem Cell 4, 336-347. 
Mani,S.A., Guo,W., Liao,M.J., Eaton,E.N., Ayyanan,A., Zhou,A.Y., Brooks,M., Reinhard,F., 
Zhang,C.C., Shipitsin,M., Campbell,L.L., Polyak,K., Brisken,C., Yang,J., and 
Weinberg,R.A. (2008). The epithelial-mesenchymal transition generates cells with 
properties of stem cells. Cell 133, 704-715. 
Matsui,W., Huff,C.A., Wang,Q., Malehorn,M.T., Barber,J., Tanhehco,Y., Smith,B.D., 
Civin,C.I., and Jones,R.J. (2004). Characterization of clonogenic multiple myeloma 
cells. Blood 103, 2332-2336. 
Mitsutake,N., Iwao,A., Nagai,K., Namba,H., Ohtsuru,A., Saenko,V., and Yamashita, 
S. (2007). Characterization of side population in thyroid cancer cell lines: cancer 
stem-like cells are enriched partly but not exclusively. Endocrinology 148, 1797-
1803. 
Morel,A.P., Lievre,M., Thomas,C., Hinkal,G., Ansieau,S., and Puisieux,A. (2008). Generation 
of breast cancer stem cells through epithelial-mesenchymal transition. PLoS. One. 3, 
e2888. 
Oshima,Y., Suzuki,A., Kawashimo,K., Ishikawa,M., Ohkohchi,N., and Taniguchi,H. (2007). 
Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met 
by flow cytometric cell sorting. Gastroenterology 132, 720-732. 
Patrawala,L., Calhoun,T., Schneider-Broussard,R., Zhou,J., Claypool,K., and Tang,D.G. 
(2005). Side population is enriched in tumorigenic, stem-like cancer cells, whereas 
ABCG2+ and A. Cancer Res. 65, 6207-6219. 
Perez-Caro,M., Cobaleda,C., Gonzalez-Herrero,I., Vicente-Duenas,C., Bermejo-Rodriguez,C., 
Sanchez-Beato,M., Orfao,A., Pintado,B., Flores,T., Sanchez-Martin,M., Jimenez,R., 
Piris,M.A., and Sanchez-Garcia,I. (2009). Cancer induction by restriction of 
oncogene expression to the stem cell compartment. EMBO J. 28, 8-20. 
Primo,D., Flores,J., Quijano,S., Sanchez,M.L., Sarasquete,M.E., del Pino-Montes,J., 
Gaarder,P.I., Gonzalez,M., and Orfao,A. (2006). Impact of BCR/ABL gene 
expression on the proliferative rate of different subpopulations of haematopoietic 
cells in chronic myeloid leukaemia. Br. J. Haematol. 135, 43-51. 
Quintana,E., Shackleton,M., Sabel,M.S., Fullen,D.R., Johnson,T.M., and Morrison,S.J.  
(2008). Efficient tumour formation by single human melanoma cells. Nature 456, 
593-598. 
www.intechopen.com
From where do Cancer-Initiating Cells Originate?   
 
45 
Reynolds,B.A. and Weiss,S. (1996). Clonal and population analyses demonstrate that an 
EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev. Biol. 
175, 1-13. 
Richardson,G.D., Robson,C.N., Lang,S.H., Neal,D.E., Maitland,N.J., and Collins,A.T. (2004). 
CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 117, 
3539-3545. 
Roesch,A., Fukunaga-Kalabis,M., Schmidt,E.C., Zabierowski,S.E., Brafford,P.A., Vultur,A., 
Basu,D., Gimotty,P., Vogt,T., and Herlyn,M. (2010). A temporarily distinct 
subpopulation of slow-cycling melanoma cells is required for continuous tumor 
growth. Cell 141, 583-594. 
Sagrinati,C., Netti,G.S., Mazzinghi,B., Lazzeri,E., Liotta,F., Frosali,F., Ronconi,E., Meini,C., 
Gacci,M., Squecco,R., Carini,M., Gesualdo,L., Francini,F., Maggi,E., Annunziato,F., 
Lasagni,L., Serio,M., Romagnani,S., and Romagnani,P. (2006). Isolation and 
characterization of multipotent progenitor cells from the Bowman's capsule of 
adult human kidneys. J. Am. Soc. Nephrol. 17, 2443-2456. 
Sebova,K. and Fridrichova,I. (2010). Epigenetic tools in potential anticancer therapy. 
Anticancer Drugs 21, 565-577. 
Sharma,S.V., Lee,D.Y., Li,B., Quinlan,M.P., Takahashi,F., Maheswaran,S., McDermott,U., 
Azizian,N., Zou,L., Fischbach,M.A., Wong,K.K., Brandstetter,K., Wittner,B., 
Ramaswamy,S., Classon,M., and Settleman,J. (2010). A chromatin-mediated 
reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80. 
Shmelkov,S.V., Butler,J.M., Hooper,A.T., Hormigo,A., Kushner,J., Milde,T., St,C.R., 
Baljevic,M., White,I., Jin,D.K., Chadburn,A., Murphy,A.J., Valenzuela,D.M., 
Gale,N.W., Thurston,G., Yancopoulos,G.D., D'Angelica,M., Kemeny,N., Lyden,D., 
and Rafii,S. (2008). CD133 expression is not restricted to stem cells, and both 
CD133+ and CD133- metastatic colon cancer cells initiate tumors. J. Clin. Invest 118, 
2111-2120. 
Stingl,J., Eirew,P., Ricketson,I., Shackleton,M., Vaillant,F., Choi,D., Li,H.I., and Eaves,C.J. 
(2006). Purification and unique properties of mammary epithelial stem cells. Nature 
439, 993-997. 
Sugiyama,T., Rodriguez,R.T., McLean,G.W., and Kim,S.K. (2007). Conserved markers of 
fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by 
FACS. Proc. Natl. Acad. Sci. U. S. A 104, 175-180. 
Thiery,J.P., Acloque,H., Huang,R.Y., and Nieto,M.A. (2009). Epithelial-mesenchymal 
transitions in development and disease. Cell 139, 871-890. 
Uchida,N., Buck,D.W., He,D., Reitsma,M.J., Masek,M., Phan,T.V., Tsukamoto,A.S., 
Gage,F.H., and Weissman,I.L. (2000). Direct isolation of human central nervous 
system stem cells. Proc. Natl. Acad. Sci. U. S. A 97, 14720-14725. 
Vesuna,F., Lisok,A., Kimble,B., and Raman,V. (2009). Twist modulates breast cancer stem 
cells by transcriptional regulation of CD24 expression. Neoplasia. 11, 1318-1328. 
Yin,A.H., Miraglia,S., Zanjani,E.D., meida-Porada,G., Ogawa,M., Leary,A.G., Olweus,J., 
Kearney,J., and Buck,D.W. (1997). AC133, a novel marker for human hematopoietic 
stem and progenitor cells. Blood 90, 5002-5012. 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
46 
Zhu,L., Gibson,P., Currle,D.S., Tong,Y., Richardson,R.J., Bayazitov,I.T., Poppleton, 
H., Zakharenko,S., Ellison,D.W., and Gilbertson,R.J. (2009). Prominin 1 marks 
intestinal stem cells that are susceptible to neoplastic transformation. Nature 457, 
603-607. 
www.intechopen.com
Cancer Stem Cells Theories and Practice
Edited by Prof. Stanley Shostak
ISBN 978-953-307-225-8
Hard cover, 442 pages
Publisher InTech
Published online 22, March, 2011
Published in print edition March, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Cancer Stem Cells Theories and Practice does not 'boldly go where no one has gone before!' Rather, Cancer
Stem Cells Theories and Practice boldly goes where the cutting edge of research theory meets the concrete
challenges of clinical practice. Cancer Stem Cells Theories and Practice is firmly grounded in the latest results
on cancer stem cells (CSCs) from world-class cancer research laboratories, but its twenty-two chapters also
tease apart cancer's vulnerabilities and identify opportunities for early detection, targeted therapy, and
reducing remission and resistance.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Stéphane Ansieau, Anne-Pierre Morel and Alain Puisieux (2011). From where do Cancer-Initiating Cells
Originate?, Cancer Stem Cells Theories and Practice, Prof. Stanley Shostak (Ed.), ISBN: 978-953-307-225-8,
InTech, Available from: http://www.intechopen.com/books/cancer-stem-cells-theories-and-practice/from-
where-do-cancer-initiating-cells-originate-
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
